Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Non-Current Debt (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Non-Current Debt for 4 consecutive years, with $14.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Debt changed N/A to $14.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $14.2 million, a N/A change, with the full-year FY2024 number at $14.3 million, changed N/A from a year prior.
  • Non-Current Debt was $14.2 million for Q3 2025 at Orchestra BioMed Holdings, down from $14.4 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $14.4 million in Q2 2025 to a low of $9.5 million in Q4 2022.
  • A 4-year average of $12.3 million and a median of $14.2 million in 2025 define the central range for Non-Current Debt.